Alloy Prescription and Intake Process: How It Works, What to Expect, and Whether It's Worth It

What Alloy Actually Is

Alloy is a telehealth company focused on prescribing hormone replacement therapy to women experiencing perimenopause and menopause symptoms. It operates as a cash-pay, direct-to-consumer brand. No insurance is accepted.

The company pairs an online symptom questionnaire with physician review to generate prescriptions for FDA-approved hormonal and non-hormonal therapies. Alloy does not manufacture its own drugs. Instead, prescriptions are filled through partner pharmacies, and products are shipped directly to patients. The model is similar to other D2C telehealth platforms like Evernow and Midi Health, though each differs in formulary scope, pricing, and clinical oversight structure. The 2022 Menopause Society position statement reaffirmed that hormone therapy remains the most effective treatment for vasomotor symptoms and should be offered to symptomatic women under age 60 or within 10 years of menopause onset 1. Alloy's formulary aligns with this guidance by centering FDA-approved estradiol and micronized progesterone.

How the Intake Process Works Step by Step

The intake begins with a structured online questionnaire. You answer questions about your menopause symptoms, medical history, current medications, and health goals. The entire form takes roughly 10 to 15 minutes.

After submission, a licensed physician reviews your responses asynchronously. This is not a live video visit. The reviewing clinician evaluates whether you are a candidate for HRT based on standard clinical criteria, including your age, time since menopause, cardiovascular risk factors, breast cancer history, and liver function status. The 2017 hormone therapy position statement from The Menopause Society specifies that the benefit-risk ratio is most favorable for women who initiate HRT before age 60 or within 10 years of menopause 2. Alloy's intake form collects the data points needed to apply these criteria.

If approved, you receive a prescription within 24 to 48 hours. The medication ships to your door. If the physician determines you are not a candidate, perhaps due to a history of estrogen-receptor-positive breast cancer or active liver disease, you receive a notification explaining why. No charge is applied for denied consultations according to Alloy's published policy.

One notable gap: Alloy does not require baseline lab work before the initial prescription. The Endocrine Society's 2015 clinical practice guideline on menopause management notes that while routine hormone level testing is not required to diagnose menopause in women over 45, baseline lipid panels and liver function tests can inform treatment decisions 3. Some competing platforms like Midi Health include lab orders as part of their standard intake.

What Medications Does Alloy Prescribe?

Alloy's formulary focuses on FDA-approved bioidentical hormones. The core offerings include transdermal estradiol patches (0.025 mg to 0.1 mg per day), oral micronized progesterone (100 mg to 200 mg capsules), and vaginal estradiol cream or inserts for genitourinary symptoms.

Transdermal estradiol carries a lower venous thromboembolism (VTE) risk compared to oral conjugated estrogens. A large nested case-control study published in the BMJ (N=80,396 VTE cases) found that transdermal estradiol did not significantly increase VTE risk (OR 0.96, 95% CI 0.88 to 1.04), while oral estrogen approximately doubled it 4. Alloy's decision to lead with patches rather than oral estrogen reflects this evidence.

For women with an intact uterus, progesterone is co-prescribed to prevent endometrial hyperplasia. The PEPI trial established that micronized progesterone provides endometrial protection comparable to medroxyprogesterone acetate while producing a more favorable lipid profile 5. Alloy uses micronized progesterone (brand name Prometrium or generic equivalent) rather than synthetic progestins.

Alloy also offers non-hormonal options for women who cannot or prefer not to use HRT. These may include paroxetine 7.5 mg (Brisdelle), the only FDA-approved non-hormonal treatment for hot flashes, and off-label gabapentin. The efficacy of paroxetine 7.5 mg was demonstrated in a phase III trial (N=1,175) showing a mean reduction of 1.66 hot flashes per day versus 1.02 for placebo at 24 weeks 6.

Is Alloy Legit? Evaluating Clinical Oversight

The legitimacy question comes up frequently in online searches. Alloy prescriptions are written by board-certified physicians or nurse practitioners licensed in the patient's state. The medications prescribed are FDA-approved and dispensed through licensed pharmacies. These are standard, evidence-based therapies recommended by The Menopause Society, the Endocrine Society, and ACOG.

The asynchronous model does raise a clinical concern. Without a live conversation, the physician cannot probe for nuance in symptom presentation or ask follow-up questions in real time. A 2021 JAMA Internal Medicine study evaluating D2C telehealth platforms found that asynchronous-only encounters had higher rates of inappropriate prescribing compared to synchronous video visits 7. Alloy does offer follow-up messaging with the prescribing clinician, but the initial evaluation is questionnaire-based only.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 on the management of menopausal symptoms recommends individualized risk assessment before initiating HRT, including evaluation of cardiovascular risk, breast cancer risk (using tools like the Gail model), and bone density status 8. Whether a structured questionnaire captures enough detail to replicate that individualized assessment is an open question.

The prescriptions themselves are legitimate. The clinical process is simplified compared to a traditional gynecology visit, and that simplification carries both benefits (speed, accessibility) and trade-offs (less personalized evaluation).

How Much Does Alloy Cost?

Alloy operates entirely outside insurance. Pricing is transparent but not inexpensive. A physician consultation plus a 90-day supply of estradiol patches and progesterone capsules typically costs between $85 and $150 per quarter, depending on the specific products and dosages selected.

For comparison, a 90-day supply of generic estradiol patches (0.05 mg/day) at a retail pharmacy with a GoodRx coupon runs approximately $30 to $75. Generic micronized progesterone 100 mg capsules cost roughly $15 to $40 for 90 capsules at retail. The Alloy price therefore includes a markup that covers the physician review, platform fees, and shipping. Women with commercial insurance or Medicare Part D coverage for these generic medications may pay less through a traditional prescriber.

The Women's Health Initiative (WHI), which shaped HRT prescribing for two decades, involved conjugated equine estrogen and medroxyprogesterone acetate, not the bioidentical formulations Alloy uses 9. The distinction matters because the WHI's risk findings (increased breast cancer, cardiovascular events) applied specifically to oral CEE plus MPA in women with a mean age of 63.3 years. Subsequent reanalysis in the WHI's 18-year follow-up showed that for women aged 50 to 59 at initiation, the risk profile was considerably more favorable 10. Alloy's formulary of transdermal estradiol and micronized progesterone reflects the shift toward formulations with better safety data, though the premium pricing means cost-conscious patients should compare options.

Alloy vs. Alternatives: Evernow, Midi Health, and Traditional Prescribers

Several D2C menopause platforms compete with Alloy. The differences matter.

Evernow uses a similar asynchronous model with physician-reviewed questionnaires. Pricing is comparable. Evernow's formulary includes compounded testosterone cream for libido concerns, which Alloy does not currently offer. The FDA has not approved testosterone therapy for women, though the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women concluded that testosterone can be prescribed for hypoactive sexual desire disorder (HSDD) in postmenopausal women when evidence-based formulations and dosing are used 11.

Midi Health takes a different approach. Midi offers synchronous video visits with menopause-trained clinicians, orders lab work, and accepts some insurance plans. The clinical model is closer to traditional care delivered via telehealth. The trade-off is less convenience: you need to schedule and attend a live appointment.

Traditional OB/GYN or menopause specialist. A 2019 survey published in Menopause found that only 20% of OB/GYN residency programs provided any menopause-specific training, leaving many practicing gynecologists undertrained in HRT prescribing 12. This training gap partly explains the rise of specialized telehealth platforms. Women whose local physicians are uncomfortable prescribing HRT may find more clinical confidence on platforms like Alloy or Midi where prescribers are specifically trained in menopause management.

The right choice depends on what you value. If speed and simplicity rank highest, Alloy's asynchronous model delivers. If you want a deeper clinical relationship, lab integration, and potential insurance coverage, Midi Health or a NAMS-certified menopause practitioner is a better fit.

What the Evidence Says About Telehealth HRT Prescribing

Telehealth prescribing for HRT is not a fringe practice. The COVID-19 pandemic accelerated regulatory acceptance of telehealth for prescription management, and multiple professional bodies have endorsed its use for appropriate indications.

A 2023 systematic review in the Journal of the American Medical Association found that telehealth-delivered chronic disease management produced clinical outcomes comparable to in-person care across multiple conditions, including medication management 13. The Menopause Society's 2023 updated position statement on hormone therapy reiterated that telehealth is an acceptable modality for initiating and managing HRT when appropriate clinical criteria are met 14.

The key clinical guardrail is patient selection. HRT is contraindicated in women with a history of breast cancer, active cardiovascular disease, undiagnosed vaginal bleeding, active liver disease, or known thrombophilia. Any prescribing platform, whether in-person or telehealth, must screen for these contraindications before issuing a prescription. Alloy's intake questionnaire addresses these risk factors directly.

One area where telehealth prescribing raises concern is follow-up monitoring. The Endocrine Society recommends reassessment of HRT at least annually, including symptom review, blood pressure check, and discussion of ongoing risks and benefits 3. Alloy offers ongoing messaging with prescribers and periodic symptom check-ins, but does not require in-person vitals or physical examination. Women using Alloy should maintain a relationship with a primary care physician for comprehensive monitoring.

Who Is a Good Candidate for Alloy?

The strongest candidates for Alloy's model are women with straightforward menopausal symptoms who have already been screened for major contraindications. A healthy 52-year-old woman experiencing moderate hot flashes and sleep disruption, with no history of breast cancer or cardiovascular disease, is the prototypical Alloy patient.

Women with complex medical histories, including prior VTE, BRCA mutations, coronary artery disease, or active liver conditions, need more thorough evaluation than an online questionnaire can provide. The same applies to women considering HRT initiation more than 10 years after menopause onset, where the cardiovascular risk window becomes less favorable per WHI subgroup analyses 10.

The 2022 Menopause Society position statement is direct: "For women aged <60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" 1. Alloy's intake process should identify women who fall within this favorable window. Whether it catches every edge case without a live clinical interview is the central limitation of any asynchronous D2C model.

Potential Limitations and What to Watch For

Alloy's model has specific gaps that prospective patients should understand before signing up.

First, the absence of required lab work means some baseline data points may be missing from your clinical record. While hormone levels are not required to diagnose menopause in women over 45 (per NICE guideline NG23), a baseline lipid panel and liver function test can guide therapy selection 15.

Second, Alloy does not prescribe testosterone. For postmenopausal women with HSDD, this represents a meaningful formulary limitation. The 2019 Global Consensus Statement supports testosterone therapy for HSDD at doses approximating premenopausal physiology (approximately 300 mcg/day transdermally) 11. Women with libido concerns may need a different platform or a specialist prescriber.

Third, the cash-pay model creates a cost barrier for women who have prescription drug coverage. Generic estradiol patches and micronized progesterone are Tier 1 or Tier 2 drugs on most commercial formularies. Insurance-covered prescriptions from a traditional provider will typically cost less per month than Alloy's bundled pricing.

Fourth, auto-ship programs require active management. If your dosage changes or your clinician recommends a drug holiday, you need to update your subscription manually. Failure to do so results in unnecessary charges and unused medication.

Women with annual household incomes below $50,000 or those on Medicaid should explore whether their state Medicaid program covers HRT before committing to a cash-pay platform. Medicaid covers estradiol and progesterone in all 50 states, though formulary restrictions and prior authorization requirements vary.